These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17017940)

  • 1. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.
    Aversa A; Bruzziches R; Pili M; Spera G
    Curr Pharm Des; 2006; 12(27):3467-84. PubMed ID: 17017940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.
    Conti CR; Pepine CJ; Sweeney M
    Am J Cardiol; 1999 Mar; 83(5A):29C-34C. PubMed ID: 10078540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
    Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase type 5 inhibithors in older males.
    Frajese GV; Pozzi F
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Rosen RC; Shaw JW
    Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
    [No Abstract]   [Full Text] [Related]  

  • 7. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
    Sommer F; Schulze W
    World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
    De Young L; Yu D; Freeman D; Brock GB
    Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.
    Cellek S; Rees RW; Kalsi J
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1563-73. PubMed ID: 12437503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction.
    Fisher WA; Rosen RC; Eardley I; Niederberger C; Nadel A; Kaufman J; Sand M
    J Sex Med; 2004 Sep; 1(2):150-60. PubMed ID: 16422969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
    Dunn ME; Althof SE; Perelman MA
    Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 13. Sexual function in hypertensive patients receiving treatment.
    Reffelmann T; Kloner RA
    Vasc Health Risk Manag; 2006; 2(4):447-55. PubMed ID: 17323599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection.
    Jackson G
    Drugs; 2004; 64(14):1533-45. PubMed ID: 15233591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
    Greco EA; Spera G; Aversa A
    Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient.
    Kloner RA
    Endocrine; 2004; 23(2-3):125-9. PubMed ID: 15146090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract]   [Full Text] [Related]  

  • 19. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.